Literature DB >> 9030556

1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo.

E P Garvey1, J A Oplinger, E S Furfine, R J Kiff, F Laszlo, B J Whittle, R G Knowles.   

Abstract

N-(3-(Aminomethyl)benzyl)acetamidine (1400W) was a slow, tight binding inhibitor of human inducible nitric- oxide synthase (iNOS). The slow onset of inhibition by 1400W showed saturation kinetics with a maximal rate constant of 0.028 s-1 and a binding constant of 2.0 microM. Inhibition was dependent on the cofactor NADPH. L-Arginine was a competitive inhibitor of 1400W binding with a Ks value of 3.0 microM. Inhibited enzyme did not recover activity after 2 h. Thus, 1400W was either an irreversible inhibitor or an extremely slowly reversible inhibitor of human iNOS with a Kd value </= 7 nM. In contrast, inhibition of human neuronal NOS and endothelial NOS (eNOS) was relatively weaker, rapidly reversible, and competitive with L-arginine, with Ki values of 2 microM and 50 microM, respectively. Thus, 1400W was at least 5000-fold selective for iNOS versus eNOS. This selectivity was similar to that observed in rat aortic rings, in which 1400W was greater than 1000-fold more potent against rat iNOS than eNOS. Finally, 1400W was greater than 50-fold more potent against iNOS than eNOS in a rat model of endotoxin-induced vascular injury. Thus, the potency and selectivity of 1400W inhibition of iNOS both in vitro and in vivo were far greater than of any previously described iNOS inhibitor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030556     DOI: 10.1074/jbc.272.8.4959

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  220 in total

1.  A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture.

Authors:  E D Franke; A Sette; J Sacci; S Southwood; G Corradin; S L Hoffman
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  A rapid and transient synthesis of nitric oxide (NO) by a constitutively expressed type II NO synthase in the guinea-pig suprachiasmatic nucleus.

Authors:  S J Starkey; A L Grant; R M Hagan
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

3.  Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase.

Authors:  T Maurer; H L Fung
Journal:  AAPS PharmSci       Date:  2000

4.  Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

5.  Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.

Authors:  E Wang; Yan Feng; Ming Zhang; Lin Zou; Yan Li; Emmanuel S Buys; Peigen Huang; Peter Brouckaert; Wei Chao
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

6.  Blood pressure normalization via pharmacotherapy improves cutaneous microvascular function through NO-dependent and NO-independent mechanisms.

Authors:  Daniel H Craighead; Caroline J Smith; Lacy M Alexander
Journal:  Microcirculation       Date:  2017-10       Impact factor: 2.628

7.  Inducible nitric oxide synthase inhibits oxygen consumption in collateral-dependent myocardium.

Authors:  Yingjie Chen; Ping Zhang; Jingxin Li; Xin Xu; Robert J Bache
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-12-06       Impact factor: 4.733

8.  Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid.

Authors:  Riku Korhonen; Riitta Korpela; Eeva Moilanen
Journal:  Inflammation       Date:  2002-10       Impact factor: 4.092

9.  Tumour necrosis factor induces phosphorylation primarily of the nitric-oxide-responsive form of glyoxalase I.

Authors:  Virginie de Hemptinne; Dieter Rondas; Joël Vandekerckhove; Katia Vancompernolle
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

10.  Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Authors:  G Wölkart; X Pang; H Stessel; M Kirchengast; F Brunner
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.